1C
AXSM icon

111 Capital’s Axsome Therapeutics AXSM Stock Holding History

111 Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450K Buy
+1,839
New +$399K 0.08% 259
2025
Q1 		– Sell
-3,291
Closed -$278K – 462
2024
Q4 		$278K Buy
+3,291
New +$303K 0.06% 313

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

111 Capital's AXSM Position: Q2 2026 in Review

111 Capital opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,839 shares worth $450K. The stake represents 0.08% of the portfolio and ranks #259 among its holdings. This is a return to the name: 111 Capital previously reported a position in AXSM as recently as Q4 2024.

111 Capital first reported a position in AXSM in Q4 2024 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • 111 Capital held 1,839 shares of Axsome Therapeutics worth $450K as of Q2 2026.
  • Axsome Therapeutics was a new 111 Capital position in Q2 2026.
  • Axsome Therapeutics made up 0.08% of 111 Capital's portfolio in Q2 2026, its #259 holding.
  • 111 Capital first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.